Pulse Biosciences (NASDAQ:PLSE) Share Price Crosses Below 50 Day Moving Average – Time to Sell?

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s share price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $19.37 and traded as low as $17.66. Pulse Biosciences shares last traded at $17.87, with a volume of 196,194 shares.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research note on Thursday, January 2nd.

Pulse Biosciences Stock Performance

The company has a 50 day moving average price of $19.37 and a 200-day moving average price of $18.47.

Insider Buying and Selling at Pulse Biosciences

In other news, Director Robert W. Duggan bought 55,256 shares of the firm’s stock in a transaction dated Friday, December 13th. The stock was purchased at an average price of $17.18 per share, with a total value of $949,298.08. Following the transaction, the director now owns 42,328,717 shares of the company’s stock, valued at approximately $727,207,358.06. The trade was a 0.13 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of Pulse Biosciences stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the sale, the chief executive officer now owns 63,172 shares in the company, valued at $1,100,456.24. This represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 71.50% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

A number of institutional investors have recently added to or reduced their stakes in PLSE. Invesco Ltd. grew its position in shares of Pulse Biosciences by 1,956.7% in the 4th quarter. Invesco Ltd. now owns 214,490 shares of the company’s stock worth $3,734,000 after buying an additional 204,061 shares during the period. Vanguard Group Inc. boosted its stake in Pulse Biosciences by 15.1% during the fourth quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company’s stock worth $19,958,000 after acquiring an additional 150,506 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Pulse Biosciences by 193.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after purchasing an additional 97,565 shares during the period. State Street Corp increased its stake in shares of Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after purchasing an additional 69,696 shares in the last quarter. Finally, Panoramic Capital LLC purchased a new position in shares of Pulse Biosciences during the fourth quarter valued at approximately $846,000. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.